Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player
Teva $TEVA has had a rough year. Plagued by crippling debt, the Israeli generics giant has undergone a massive reckoning that culminated in an executive exodus and a reorganization of the business. Matters went from bad to worse earlier this month when its migraine drug that was pegged to revive its fortunes was snubbed by US pharmacy benefit manager Express Scripts $ESRX in favor of rival treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.